Complex formation between human prostate-specific antigen and protease inhibitors in mouse plasma

Prostate

Volumn 70, Issue 5, 2010, Pages 482-490

  Hekim, Can ^a   Riipi, Tero ^a   Zhu, Lei ^a   Laakkonen, Pirjo ^b,c   Stenman, Ulf Håkan ^a   Koistinen, Hannu ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Antitrypsin; Serpin; Xenograft tumor

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR; TRYPSIN; ALPHA 1 ANTICHYMOTRYPSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GRAFT; CANCER MODEL; CELL STRAIN 22RV1; CELL STRAIN LNCAP; COMPLEX FORMATION; CONTROLLED STUDY; EXTRACTION; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOREACTIVITY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PURIFICATION; XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; CANCER TRANSPLANTATION; FEMALE; METABOLISM; MOLECULAR GENETICS; TUMOR CELL LINE;

ALPHA 1-ANTICHYMOTRYPSIN; ALPHA 1-ANTITRYPSIN; ALPHA-MACROGLOBULINS; AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PROSTATE-SPECIFIC ANTIGEN; PROTEASE INHIBITORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 77949911064     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21082     Document Type: Article

References (53)

1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17(2):159-163.
2. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76(5):1899-1903.
3. Coombs GS, Bergstrom RC, Pellequer JL, Baker SI, Navre M, Smith MM, Tainer JA, Madison EL, Corey DR. Substrate specificity of prostate-specific antigen (PSA). Chem Biol 1998;5(9):475-488. (Pubitemid 28436726)
4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909-916.
5. Stenman UH. Prostate-specific antigen, clinical use and staging: An overview. Br J Urol 1997;79 (suppl 1):53-60. (Pubitemid 127748036)
6. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194(3):755-763.
7. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51(1):222-226.
8. Zhang WM, Leinonen J, Kalkkinen N, Stenman UH. Prostate-specific antigen forms a complex with and cleaves alpha 1-protease inhibitor in vitro. Prostate 1997;33(2):87-96. (Pubitemid 27415532)
9. Zhang WM, Finne P, Leinonen J, Salo J, Stenman UH. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology 2000;56(2):267-272.
10. Lilja H, Cockett AT, Abrahamsson PA. Prostate specific antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum. Cancer 1992;70 (1 suppl):230-234.
11. Lilja H. Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. Urol Clin North Am 1993;20(4):681-686.
12. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman UH. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem 1999;45(6 Pt 1):814-821. (Pubitemid 29266611)
13. Finne P, Zhang WM, Auvinen A, Leinonen J, Maattanen L, Rannikko S, Tammela TL, Stenman UH. Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer. J Urol 2000;164(6):1956-1960. (Pubitemid 33647108)
14. Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999;91(19):1635-1640.
15. Abrahamsson PA, Lilja H, Falkmer S, Wadström LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988;12(1):39-46.
16. Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 2000;6(1):160-165. (Pubitemid 30064989)
17. Lintula S, Stenman J, Bjartell A, Nordling S, Stenman UH. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 2005;63(4):324-329. (Pubitemid 40664343)
18. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A, Stenman UH, Bjartell A. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol 2007;52(6):1670-1679.
19. Papadopoulos I, Sivridis E, Giatromanolaki A, Koukourakis MI. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res 2001;7(6):1533-1538. (Pubitemid 32708616)
20. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995;1(10):1089-1094.
21. Ishii K, Otsuka T, Iguchi K, Usui S, Yamamoto H, Sugimura Y, Yoshikawa K, Hayward SW, Hirano K. Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett 2004;207(1):79-87. (Pubitemid 38429889)
22. Pezzato E, Sartor L, Dell'Aica I, Dittadi R, Gion M, Belluco C, Lise M, Garbisa S. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. Int J Cancer 2004;112(5):787-792. (Pubitemid 39435263)
23. Koistinen H, Närvänen A, Pakkala M, Hekim C, Mattsson JM, Zhu L, Laakkonen P, Stenman UH. Development of peptides specifically modulating the activity of KLK2 and KLK3. Biol Chem 2008;389(6):633-642.
24. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res 1997;57(8):1584-1589. (Pubitemid 27175579)
25. Ferro MA, Gillatt D, Symes MO, Smith PJ. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology 1989;34(3):134-138.
26. Dixon SC, Knopf KB, Figg WD. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 2001;53(1):73-91. (Pubitemid 32173108)
27. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman U-H, Stephan C, Talieri M, Yousef GM. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 2006;387(6):637-641. (Pubitemid 43964785)
28. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT., Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001;48(1):1-6.
29. Buhler KR, Corey E, Stray JE, Vessella RL. Study of free and complexed prostate-specific antigen in mice bearing human prostate cancer xenografts. Prostate 1998;36(3):194-200. (Pubitemid 28341132)
30. DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, Wai J, Senderak ET, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Freidinger R, Huff J, Oliff A, Jones RE. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 2000;6(11):1248-1252.
31. Khan SR, Denmeade SR. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. Prostate 2000;45(1):80-83.
32. Wu P, Leinonen J, Koivunen E, Lankinen H, Stenman UH. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur J Biochem 2000;267(20):6212-6220.
33. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S, Stenman UH. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem 1998;44(12):2471-2479. (Pubitemid 28565659)
34. Wu P, Stenman UH, Pakkala M, Narvanen A, Leinonen J. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography. Prostate 2004;58(4):345-353. (Pubitemid 38295028)
35. Leinonen J, Wu P, Stenman UH. Epitope mapping of antibodies against prostate-specific antigen with use of peptide libraries. Clin Chem 2002;48(12):2208-2216. (Pubitemid 35397564)
36. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68(5):850-858. (Pubitemid 26101214)
37. Lipman DJ, Pearson WR. Rapid and sensitive protein similarity searches. Science 1985;227(4693):1435-1441.
38. Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995;41(11):1567-1573.
39. Baumgart Y, Otto A, Schafer A, Usbeck E, Cott C, Schott A, Tornack M, Wenzel A, Mossie A, Birkenmeier G. Characterization of novel monoclonal antibodies for prostate-specific antigen (PSA) with potency to recognize PSA bound to alpha 2-macroglobulin. Clin Chem 2005;51(1):84-92. (Pubitemid 40024016)
40. Salvesen GS, Barrett AJ. Covalent binding of proteinases in their reaction with alpha 2-macroglobulin. Biochem J 1980;187(3):695-701.
41. Sottrup-Jensen L, Hansen HF, Mortensen SB, Petersen TE, Magnusson S. Sequence location of the reactive thiol ester in human alpha 2-macroglobulin. FEBS Lett 1981;123(1):145-148.
42. Miyata K, Nakamura M, Tomoda K. Interaction between Serratia protease and human plasma alpha 2 macroglobulin. J Biochem 1981;89(4):1231-1237.
43. Barrett AJ, Starkey PM. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 1973;133(4):709-724.
44. Law RH, Zhang Q, McGowan S, Buckle AM, Silverman GA, Wong W, Rosado CJ, Langendorf CG, Pike RN, Bird PI, Whisstock JC. An overview of the serpin superfamily. Genome Biol 2006;7(5):216.
45. Villoutreix BO, Lilja H, Pettersson K, Lövgren T, Teleman O. Structural investigation of the alpha-1-antichymotrypsin: Prostate- specific antigen complex by comparative model building. Protein Sci 1996;5(5):836-851. (Pubitemid 26139171)
46. Dafforn TR, Pike RN, Bottomley SP. Physical characterization of serpin conformations. Methods 2004;32(2):150-158.
47. Johnson D, Travis J. Structural evidence for methionine at the reactive site of human alpha-1-proteinase inhibitor. J Biol Chem 1978;253(20):7142-7144.
48. Patston P, Gettins P, Beechem J, Schapira M. Mechanism of serpin action: Evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 1991;30(36):8876-8882.
49. Zhou A. The serpin inhibitory mechanism is critically dependent on the length of the reactive center loop. J Biol Chem 2001;276(29):27541-27547. (Pubitemid 37410673)
50. Gettins PG. Serpin structure, mechanism, and function. Chem Rev 2002;102(12):4751-4804.
51. Schechter NM, Plotnick MI. Measurement of the kinetic parameters mediating protease-serpin inhibition. Methods 2004;32(2):159-168.
52. Bjartell A, Bjork T, Matikainen MT, Abrahamsson PA, di Sant'Agnese A, Lilja H. Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology 1993;42(5):502-510.
53. Lattin JE, Schroder K, Su AI, Walker JR, Zhang J, Wiltshire T, Saijo K, Glass CK, Hume DA, Kellie S, Sweet MJ. Expression analysis of G protein-coupled receptors in mouse macrophages. Immunome Res 2008;4(1):5.